Sahajanand Medical Technologies IPO Swells to 14.2× Subscription on Final Bidding Day

By the time the clock struck 5:20 pm on October 19, the Sahajanand Medical Technologies IPO had already been drenched in demand – an overall subscription of 14.20 times, according to NSE data. It was a whirlwind of bids, with investors of every stripe scrambling for a slice of the offering.

Let’s break it down. The company put 97,50,482 shares on the table, but the market answered with a whopping 13,84,72,771 bids. That translates to more than fourteen times the supply being chased. Institutional investors were the real fire‑crackers, lodging bids at 34.70× the offer size. Non‑institutional players weren’t far behind, subscribing at 14.64×, while retail investors managed a respectable 3.03×.

On the grey‑market front, the shares were quoted with an 8 % premium on the morning of the final day, as per InvestorGain. Remember, though, that grey‑market premiums are merely a pulse‑check on speculative trading – they don’t guarantee what will happen when the stock actually lists.

Financially, the IPO was structured as an Offer‑for‑Sale (OFS) aimed at raising up to Rs 475.48 crore. Ahead of the public issue, the company had already secured Rs 140.06 crore from anchor investors. In the anchor book, eight institutional investors were allotted 40.71 lakh equity shares at the top of the price band on October 14.

Of that anchor allocation, five domestic mutual‑fund houses – Nippon Life India, DSP Mutual Fund, WhiteOak Capital, Invesco India, and UTI AMC – together took home about 30.25 lakh shares, roughly Rs 104 crore worth. Other big‑ticket names such as Allianz Global Investors Fund, Tata AIA Life Insurance, and Natixis International Funds also featured in the anchor book.

What does Sahajanand actually make? The firm specialises in Class III and Class C/D medical devices, with a strong focus on vascular‑intervention gear like coronary stents and balloons, as well as structural‑heart products such as TAVI devices and occluders. Its catalogue even stretches to renal stents and peripheral drug‑coated balloons.

The IPO was managed by a consortium of merchant bankers – Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities and Capital Markets (India), and Nuvama Wealth Management – each playing a role in steering the issue to the finish line.

All said and done, the Sahajanand Medical Technologies IPO not only hit its fundraising target but also sparked robust enthusiasm across the investor spectrum, setting the stage for a promising market debut.